Skip to main content
SpringerLink
Log in

H2-Blocker bei Erkrankungen mit pathologisch gesteigerter Säuresekretion

  • Conference paper
H2-Blocker in der Therapie säurebedingter Erkrankungen

  • 19 Accesses

Zusammenfassung

Seit Einführung von H2-Rezeptorantagonisten ist es möglich, Patienten mit pathologisch gesteigerter Säuresekretion (überwiegend mit Zollinger-Ellison-Syndron, ZES) über kurze Zeit medikamentös wirkungsvoll zu behandeln [1–3]. Die früher notfallmäßig durchgeführte totale Gastrektomie wurde somit weitgehend überflüssig. Folgestudien zeigten, daß dieses Krankheitsbild auch über einen längeren Zeitraum mit H2-Blockern beherrscht werden kann [4–9]. Allerdings ist eine Langzeittherapie mit Cimetidin nicht unproblematisch [10–14]. Während in einigen Studien mehr als 90% der Patienten mit ZES über einen Zeitraum bis zu 7 Jahren erfolgreich behandelt werden konnten, berichteten andere Autoren über eine relativ hohe Rate sog. Cimetidinversager [4, 7, 10–12, 14]. Eine Langzeittherapie wird auch dadurch kompliziert, daß bei ca. 60% der Patienten die Cimetidindosis gesteigert werden muß [4, 14]. Auch muß Cimetidin in relativ kurzfristigen Zeitabständen tagsüber und in der Nacht verabreicht werden [4, 14]. 8–50% aller männlichen Patienten mit pathologisch gesteigerter Säuresekretion entwickeln unter einer hochdosierten Cimetidintherapie Impotenz, Gynäkomastie und Brustspannung [12, 14, 16].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. McCarthy DM, Olinger EJ, May RJ, Long BW, Gardner JD (1977) H2-histamine receptor blocking agents in the Zollinger-Ellison syndrome. Ann Intern Med 87: 668–674

    PubMed  CAS  Google Scholar 

  2. Richardson CT, Walsh JH (1976) The value of a histamine H2-receptor antagonist in the management of patients with the Zollinger-Ellison syndrome. N Engl J Med 294:133–135

    Article  PubMed  CAS  Google Scholar 

  3. Bonfils S, Mignon M, Jian R, Kloeti G (1977) Biological studies during long-term Cimetidine administration in Zollinger-Ellison syndrome. In: Burland WL, Simkins MA (Hrsg.) Cimetidine: Proceedings of the Second International Symposium on histamine H2-receptor antagonists. Excerpta Medica Amsterdam Oxford Princeton, 311–321

    Google Scholar 

  4. Jensen RT, Gardner JD, Raufman JP, Pandol SJ, Doppman JL, Collen MJ (1983) Zollinger-Ellllison syndrome. NIH combined clinical staff conference (Jensen RT, Moderator). Ann Intern Med 98:59–75

    PubMed  CAS  Google Scholar 

  5. Bonfils S, Mignon M, Gratton J (1979) Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome. World J Surg 3:597–604

    Article  PubMed  CAS  Google Scholar 

  6. Stadil F, Stage JG (1978) Cimetidine and the Zollinger-Ellisonsyndrome. In: Wastell C, Lance P (Hrsg.) Cimetidine. The Westminster Hospital Symposium. Churchill Livingstone, London, 91–104

    Google Scholar 

  7. Malagelada JR, Edis AJ, Adson MA, Von Heerden JA, Go VLW (1983) Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84:1524–1532

    PubMed  CAS  Google Scholar 

  8. Deveney CW, Deveney KS, Way LW (1978) The Zollinger-Ellison syndrome — 23 years later. Ann Surg 188:384–393

    Article  PubMed  CAS  Google Scholar 

  9. McCarthy DM (1978) Report on the United States experience with Cimetidine in Zollinger-Ellison syndrome and other hypersecretory states. Gastroenterology 74:453–458

    PubMed  CAS  Google Scholar 

  10. Stabile BE, Ippoliti AF, Walsh JH, Passaro E Jr (1983) Failure of histamine H2-receptor antagonist therapy in Zollinger-Ellison syndrome. Am J Surg 145:17–23

    Article  PubMed  CAS  Google Scholar 

  11. Deveney CW, Stein S, Way LW (1983) Cimetidine in the treatment of Zollinger-Ellison syndrome. Am J Surg 146:116–123

    Article  PubMed  CAS  Google Scholar 

  12. Mignon M, Vallot T, Hervoir P, Benfredj P, Bonfils S (1982) Ranitidine versus Cimetidine in the management of Zollinger-Ellison syndrome. In: Riley AJ, Salmon RP (Hrsg.) Ranitidine: Proceedings of an International Symposium held in the context of the Seventh World Congress of Gastroenterology. Excerpta Medica, Amsterdam Oxford Princeton, 169–177

    Google Scholar 

  13. Jensen RT (to be published) Basis for failure of Cimetidine in patients with Zollinger-Ellison syndrome. Zur Publikation eingereicht

    Google Scholar 

  14. Jensen RT, Pandol SJ, Collen MJ, Raufman JP, Gardner JD (1983) Diagnosis and management of the Zollinger-Ellison syndrome. J Clin Gastroenterol [Suppl 1] 5:123–131

    Article  PubMed  Google Scholar 

  15. Collen MJ, Howard JM, McArthur KE, et al (1984) Comparison of ranitidine and Cimetidine in the treatment of gastric hypersecretion. Ann Intern Med 100:52–58

    PubMed  CAS  Google Scholar 

  16. Jensen RT, Collen MJ, Pandol SJ, et al (1983) Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 308:883–887

    Article  PubMed  CAS  Google Scholar 

  17. Anonymous (1982) Cimetidine and ranitidine. Lancet I:601–602

    Google Scholar 

  18. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer diseases and other allied diseases. Drugs 24:267–303

    Article  PubMed  CAS  Google Scholar 

  19. Funder JW, Mercer JE (1979) Cimetidine, a histamine H2-receptor antagonist occupies androgen receptors. J Clin Endocrinol Metab 48:189–191

    Article  PubMed  CAS  Google Scholar 

  20. Pearce P, Funder JP (1980) Histamine H2-receptor antagonist: Radioreceptor assay for antiandrogen side-effects. Clin Exp Pharmacol Physiol 7:442

    Google Scholar 

  21. Zeldis JB, Feldman LS, Isselbacher KJ (1983) Ranitidine: A new H2-receptor antagonist. N Engl J Med 309:1368–1373

    Article  PubMed  CAS  Google Scholar 

  22. Danilewitz M, Ou Tim L, Hirschowitz B, (1982) Ranitidine suppression of gastric hypersecretion resistant to Cimetidine. N. Engl J Med 306:20–22

    Article  PubMed  CAS  Google Scholar 

  23. Raufman JP, Collins SM, Pandol SJ, et al (1983) Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 84:108–113

    PubMed  CAS  Google Scholar 

  24. Pedrazzoli S, Pasquali C, Zannini G, Pregonese V, Bertola G, Petrin P (1982) Use of Cimetidine and ranitidine in the medical treatment of Zollinger-Ellison syndrome (Abstract). Scand J Gastroenterol [Suppl 78] 17:A1009

    Google Scholar 

  25. Barr GD, Piper DW (1981) Possible ranitidine hepatitis. Med J Aust 2:421

    PubMed  CAS  Google Scholar 

  26. Villeneuve JP, Warner HA (1979) Cimetidine hepatitis. Gastroenterology 77:143–144

    PubMed  CAS  Google Scholar 

  27. McGuigan JE (1981) A consideration of the aderse effects of Cimetidine. Gastroenterology 80:181 – 192

    PubMed  CAS  Google Scholar 

  28. Simon B, Müller P, Dammann HG, Kommereil B (1982) Adverse effects of Cimetidine and safety profile of ranitidine. In: Misiewicz JJ, Wormsley KG (Hrsg.) The clinical use of ranitidine. Symposium series 5, Medicine Publishing Foundation, Oxford, 58–65

    Google Scholar 

  29. Kimelblatt BJ, Cerra FB, Called G, Berg MJ, McMillen MA, Schentag JJ (1980) Dose and serum concentration relationships in cimetidine-associated mental confusion. Gastroenterology 78:791–795

    PubMed  CAS  Google Scholar 

  30. Powell JR, Donn KH (1983) The pharmacokinetics for H2-antagonist drug interactions: Concepts and implications. J Clin Gastroenterol [Suppl 1] 5:95–113

    Article  PubMed  Google Scholar 

  31. Simon B, Müller P, Dammann HG (1982) Safety profile of ranitidine. In: Riley AJ, Salmon PR (Hrsg.) Ranitidine: Proceedings of an International Symposium held in the context of the Seventh World Congress of Gastroenterology. Excerpta Medica, Amsterdam Oxford Princeton, 181–189

    Google Scholar 

  32. Moebius UM (1982) Ranitidine side-effects. Lancet II:1053–1054

    Google Scholar 

  33. Camarri E, Chirone E, Panteria G, Zocchi M (1982) Ranitidine induced bradycardia. Lancet II: 160

    Article  Google Scholar 

  34. Dobrilla G, Felder M, Chilovi F, de Pretis G (1982) Exacerbation of glaucoma associated with both Cimetidine and ranitidine. Lancet I:1078

    Article  Google Scholar 

  35. Bertaccini G, Coruzzi G (1982) Cholinergic-like effects of the new histamine H2-receptor antagonist ranitidine. Agents Actions 12:168–171

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institutes of Health, Bethesda, MD, 20205, Building 10, Room 9C-103, USA

    M. J. Collen, J. D. Gardner & R. T. Jensen

Authors
  1. M. J. Collen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. D. Gardner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. T. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ninewells Hospital, DD1 9SY, Dundee, Scotland, GB

    Kenneth G. Wormsley MD

  2. Krankenhaus Bethanien, Martinistraße 44, D-2000, Hamburg 20, Deutschland

    Hans-Gerd Dammann

  3. Gastroenterologische Abteilung, Med. Universitätsklinik Heidelberg, Bergheimer Straße 58, D-6900, Heidelberg 1, Deutschland

    Bernd Simon

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Collen, M.J., Gardner, J.D., Jensen, R.T. (1984). H2-Blocker bei Erkrankungen mit pathologisch gesteigerter Säuresekretion. In: Wormsley, K.G., Dammann, HG., Simon, B. (eds) H2-Blocker in der Therapie säurebedingter Erkrankungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70040-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-70040-8_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-13800-6

  • Online ISBN: 978-3-642-70040-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation